Topic resource collection
Approved comparison material connected to this topic.
7 resourcesRead both sides
The table below contrasts peptides for ADHD with FDA-approved stimulant medications across mechanism, evidence base, regulatory status, and clinical utility. Prescription Stimulants (methylphenidate, amphetamine) Dopamine and nor…
The distinction between cognitive enhancement and ADHD symptom management is not semantic—it's mechanistic. ADHD involves dysregulation of dopamine transporter (DAT) density in the striatum, reduced norepinephrine signaling in th…
| Peptide | Mechanism of Action | Strongest Evidence Base | Administration Route | Dosing Protocol (Published) | ADHD-Specific Data | Professional Assessment ||—|—|—|—|—|—|| Cerebrolysin | BDNF/NGF upregulation, NMDA modulation |…
Semax Increases dopamine/norepinephrine turnover via BDNF-mediated tyrosine hydroxylase upregulation Intranasal 0.1–0.3% solution, 2–3 drops per nostril twice daily 7–14 days for measurable attentional improvements Best-suited fo…
Cerebrolysin BDNF upregulation, synaptic plasticity enhancement Inattentive-type: working memory deficits, sustained attention 2–3 times per week, 5–10 mL per dose Most evidence-backed for cognitive enhancement; requires IM injec…
Cerebrolysin BDNF-like neurotrophic signaling Synaptic plasticity, dendritic arborisation Improved cognitive flexibility, working memory retention 10–30 mL IV daily (clinical); 1–5 mg/kg subcutaneous (research) Strongest evidence…
Dihexa HGF receptor agonist; stimulates synaptogenesis in prefrontal cortex 40–60% oral; crosses BBB efficiently 0.25–2mg daily, oral or subcutaneous Increased synaptic density 300% in rodent PFC; sustained cognitive benefit 4 we…